BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20340136)

  • 1. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
    McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
    Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.
    Scaini MC; Rossi E; de Siqueira Torres PL; Zullato D; Callegaro M; Casella C; Quaggio M; Agata S; Malacrida S; Chiarion-Sileni V; Vecchiato A; Alaibac M; Montagna M; Mann GJ; Menin C; D'Andrea E
    Mutat Res; 2009 Dec; 671(1-2):26-32. PubMed ID: 19712690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
    Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
    Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
    Becker TM; Rizos H; Kefford RF; Mann GJ
    Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-terminal domain of p16(INK4a) is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells.
    Fahham N; Sardari S; Ostad SN; Vaziri B; Ghahremani MH
    J Cell Biochem; 2010 Dec; 111(6):1598-606. PubMed ID: 21053367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
    Jones R; Ruas M; Gregory F; Moulin S; Delia D; Manoukian S; Rowe J; Brookes S; Peters G
    Cancer Res; 2007 Oct; 67(19):9134-41. PubMed ID: 17909018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
    Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
    Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
    Newton Bishop JA; Harland M; Bennett DC; Bataille V; Goldstein AM; Tucker MA; Ponder BA; Cuzick J; Selby P; Bishop DT
    Br J Cancer; 1999 Apr; 80(1-2):295-300. PubMed ID: 10390011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of germline CDK6 mutations in familial melanoma.
    Shennan MG; Badin AC; Walsh S; Summers A; From L; McKenzie M; Goldstein AM; Tucker MA; Hogg D; Lassam N
    Oncogene; 2000 Mar; 19(14):1849-52. PubMed ID: 10777219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF.
    Rizos H; Puig S; Badenas C; Malvehy J; Darmanian AP; Jiménez L; Milà M; Kefford RF
    Oncogene; 2001 Sep; 20(39):5543-7. PubMed ID: 11571653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
    Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
    Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis].
    Soufir N; Basset-Seguin N
    Bull Cancer; 2001 Nov; 88(11):1061-7. PubMed ID: 11741799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
    Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
    Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.
    Ruas M; Gregory F; Jones R; Poolman R; Starborg M; Rowe J; Brookes S; Peters G
    Mol Cell Biol; 2007 Jun; 27(12):4273-82. PubMed ID: 17420273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel and recurrent p14 mutations in Italian familial melanoma.
    Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
    Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.